<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877160</url>
  </required_header>
  <id_info>
    <org_study_id>AL-794-803</org_study_id>
    <nct_id>NCT02877160</nct_id>
  </id_info>
  <brief_title>A Study to Assess the PK of AL-794 Formulations in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Open-Label, Single-Dose, Crossover Study to Assess the Pharmacokinetics, Including Food Effect, of AL-794 Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alios Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alios Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, randomized, open-label crossover study to assess the
      pharmacokinetics and food effect of AL-794 formulations in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time of dosing to infinity (AUC0-inf) of ALS-033719 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions.</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by AEs</measure>
    <time_frame>From screening to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by Clinical lab results</measure>
    <time_frame>From screening to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by 12-lead ECGs</measure>
    <time_frame>From screening to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by Vital signs</measure>
    <time_frame>From screening to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as determined by Physical examinations</measure>
    <time_frame>From screening to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of ALS-033719 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions.</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time of dosing to last quantifiable concentration (AUC0-last) of ALS-033719 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions.</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: time of the maximum concentration (tmax)</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: terminal elimination half-life (t1/2)</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: Cmax</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: tmax</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: t1/2</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: AUC0-inf</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033927 in plasma following single dose administration of test formulation and reference formulation of AL-794 under fasted conditions: AUC0-last</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033719 and ALS-033927 in plasma after a single oral dose of test formulation under fed conditions: Cmax</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033719 and ALS-033927 in plasma after a single oral dose of test formulation under fed conditions: Tmax</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033719 and ALS-033927 in plasma after a single oral dose of test formulation under fed conditions: AUC 0-inf</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ALS-033719 and ALS-033927 in plasma after a single oral dose of test formulation under fed conditions: AUC 0-last</measure>
    <time_frame>From Day 1 (Prior to dosing) to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Reference Formulation Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of AL-794 study drug in suspension dosed in a fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Formulation Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Formulation Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-794 suspension</intervention_name>
    <arm_group_label>Reference Formulation Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-794 tablet</intervention_name>
    <arm_group_label>Test Formulation Fasted</arm_group_label>
    <arm_group_label>Test Formulation Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided written consent.

          2. In the investigator's opinion, the subject is able to understand and comply with
             protocol requirements, instructions, and protocol-stated restrictions and is likely to
             complete the study as planned.

          3. Subject is in good health as deemed by the investigator, based on the findings of a
             medical evaluation including medical history, physical examination, laboratory tests
             and ECG.

          4. Male or female, 18-60 years of age.

          5. Body mass index (BMI) 18-30 kg/m2, inclusive. The minimum weight is 50 kg.

          6. A female subject is eligible to participate in this study if she is of
             non-childbearing potential or postmenopausal.

          7. If male, subject is surgically sterile or practicing acceptable forms of birth control
             until 90 days after the end of the study. Males must agree to refrain from sperm
             donation from check-in through 90 days after dosing.

        Exclusion Criteria:

          1. Men whose female partners are pregnant or contemplating pregnancy from the date of
             screening until 90 days after their last dose of study drugs.

          2. Clinically significant laboratory abnormalities or abnormalities which are deemed to
             interfere with the ability to interpret study data.

          3. Creatinine clearance of less than 60 mL/min (MDRD).

          4. Total bilirubin, ALT, AST, or Alkaline Phosphatase &gt;1.2Ã—ULN (documented Gilbert's
             permitted).

          5. Clinically significant cardiovascular, respiratory, renal, gastrointestinal,
             hematologic, neurologic, thyroid or any other medical illness or psychiatric disorder,
             as determined by the Investigator and/or Sponsor's Medical Monitor.

          6. Positive screening test for influenza, hepatitis A, B, C or HIV serology.

          7. Any condition that, in the opinion of the investigator, would compromise the study's
             objectives or the well-being of the subject or prevent the subject from meeting the
             study requirements.

          8. Participation in an investigational drug trial or having received an investigational
             vaccine within 3 months or 5 half-lives (whichever is longer) prior to study
             medication.

          9. Clinically significant abnormal ECG findings. Particularly, a history or family
             history of prolonged QT syndrome (eg, torsade de pointes), pre-existing sinus node
             disease, (incomplete) AV block, heart failure, or sudden cardiac death; or a corrected
             QT interval (QTcF or QTcB) &gt;450 milliseconds for male subjects and &gt;470 milliseconds
             for female subjects at the screening visit.

         10. Clinically significant blood loss or elective blood donation of significant volume
             (ie, &gt;500 mL) within 90 days of first dose of study drug; &gt;1 unit of plasma within 7
             days of first dose of study drug.

         11. Clinically significant abnormal heart rate, respiratory rate, temperature or blood
             pressure values outside of the normal range, per local standards (evaluated in a
             semi-recumbent or recumbent position after 5 minutes of rest) which are considered
             clinically significant. One repeat measurement after an additional 5 minutes of rest
             is permitted in one visit day.

         12. Evidence of clinically significant infection within 2 weeks prior to admission.

         13. Unwilling to abstain from alcohol for at least 1 week prior to the start of dosing
             through the Study Completion visit.

         14. History of regular alcohol intake &gt;14 units per week of alcohol for females and &gt;21
             units per week for males (one unit is defined as 8 g alcohol) within 3 months of the
             screening visit.

         15. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of
             Mental Disorders (5th edition) (DSM-V) criteria within 1 year before screening or
             positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates,
             opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening or Day
             1.

         16. History of tobacco use or used nicotine-containing products within 3 months of the
             screening visit.

         17. The subject has a positive prestudy drug screen.

         18. The use of concomitant medications, including prescription, over the counter
             medications, herbal medications, inducers or inhibitors of CYP enzymes,
             glucuronidation or drug transporters (including P-glycoprotein and OATP1B1) within 14
             days or 5 half-lives (whichever is longer) prior to the first dose of study medication
             is excluded, unless approved by the Sponsor's Medical Monitor. Occasional use of
             paracetamol, or its equivalent, is permitted.

         19. Exposure to more than 4 new investigational entities within 12 months prior to the
             first dosing day.

         20. Hypersensitivity to the active substances or to any of the excipients of AL-794, or
             prior dosing with AL-794.

         21. Unwillingness or inability to comply with the study protocol for any other reason.

         22. Employee of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator or employees of Johnson &amp;
             Johnson.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adeep Puri</last_name>
    <role>Principal Investigator</role>
    <affiliation>HMR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

